PATENT CLAIM ANALYSIS

Application Number: 16106104
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "301000"]

Abstract:
The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

Claim (Index 6):
A compound as in  claim 4 , wherein\n R 1  is hydroxy-methyl-; R 2  and R 3  are taken together with the carbon atoms to which they are bound to form 2,3-dihydro-furanyl; R 4  is selected from the group consisting of hydroxy, chloro, methyl, ethyl, methoxy and ethoxy; R 5  and R 6  are each hydrogen;  is selected from the group consisting of benzothien-2-yl, chroman-6-yl, 2,3-dihydro-benzo[b][1,4]dioxin-6-yl, 2,3-dihydro-benzo[b][1,4]oxathiin-6-yl, bicyclo[4.2.0]octa-1 (6),2,4-trien-3-yl, 3,3-dideutero-2,3-dihydro-benzo[b][1,4]dioxin-6-yl and 2,2,3,3-tetradeutero-2,3-dihydro-benzo[b][1,4]dioxin-6-yl; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 96.0
- Lexical Diversity: 1.08108
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14593071', '16059072', '16059074', '13634597', '14122836']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8357953512045332
- 35 USC 102 Novelty (BERT): 0.5270190694902595
- Combined Prediction Score: 0.8049177230331058
- Mean Citation Score: 351.143048
- Max Citation Score: 357.37866
- Similarity Product: 307.19206941588885

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test